Altesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations

Study objective is to demonstrate that treatment with vapendavir can mitigate or prevent worsening of respiratory symptoms caused by rhinovirus, which often lead to increased need for medical interventions ATLANTA, May 5, 2026 /PRNewswire/ -- Altesa BioSciences, a clinical-stage...